-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-05-19
A recent study reveals that naturally occurring angiotensin peptides, including Angiotensin III, significantly enhance binding of the SARS-CoV-2 spike protein to the host AXL receptor. This work provides mechanistic insight into potential links between the renin–angiotensin–aldosterone system (RAAS) and COVID-19 pathogenesis, with implications for both cardiovascular and infectious disease research.
-
Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel
2026-05-18
This study demonstrates that fucoidan—a sulfated α-L-fucan from brown algae—selectively reduces caveolin-1 expression in MCF-7 breast cancer cells, revealing a novel mechanism for its antitumor activity. The findings suggest caveolin-1 modulation as a promising therapeutic strategy and provide new impetus for translational research on anticancer polysaccharides.
-
Oseltamivir Acid: Influenza Neuraminidase Inhibitor Benchmar
2026-05-18
Oseltamivir acid is a potent influenza neuraminidase inhibitor and active metabolite of oseltamivir phosphate. It directly inhibits viral sialidase activity, interrupting influenza virus replication and spread. Research demonstrates robust in vitro and in vivo efficacy, but resistance via H275Y mutation is a significant limitation.
-
ATM Inhibition with Fenofibrate: Synergy in Ovarian Cancer C
2026-05-17
This study demonstrates that ATM kinase inhibition synergizes with the metabolic drug fenofibrate to induce senescence in high grade serous ovarian cancer (HGSOC) cells. The findings highlight a new combinatorial approach for treating HR-proficient HGSOC, which is often resistant to current therapies.
-
Kaempferol’s Inhibition of Ferroptosis in Vitiligo via NF-κB
2026-05-16
This study uncovers the mechanism by which kaempferol protects human melanocytes from ferroptosis in vitiligo, implicating the NF-κB/PTGS2 signaling axis as a critical mediator. The findings highlight new therapeutic targets for oxidative stress-driven melanocyte loss and offer a mechanistic framework for ferroptosis modulation in depigmenting disorders.
-
Dual Inhibition of FUBP1 and Topoisomerase I by SN-38 in Can
2026-05-15
This study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), beyond its established role as a topoisomerase I inhibitor, directly impedes the binding of the oncogenic transcription regulator FUBP1 to its DNA target sequence FUSE. The findings expand the mechanistic understanding of SN-38 and camptothecin analogs, suggesting their dual action could enhance therapeutic strategies in hepatocellular and colorectal cancers.
-
Thioredoxin 1 Regulates Lens Iron Metabolism in Late Oxidati
2026-05-15
This study identifies Thioredoxin 1 (Trx1) as a novel regulator of iron metabolism during the late stage of oxidative damage in lens tissue, a key process in age-related cataract formation. By elucidating the interplay between Trx1, iron homeostasis, and antioxidant defense, the findings provide new targets for mitigating cataract progression.
-
Fludarabine: Redefining Antigen Presentation in Oncology Res
2026-05-14
This article offers translational researchers a mechanistic and strategic exploration of Fludarabine’s dual role as a DNA synthesis inhibitor and a dynamic modulator of tumor immunogenicity. Synthesizing recent mechanistic insights—including evidence of Fludarabine’s impact on antigen presentation and synergy with adoptive cell therapies—this piece delivers actionable guidance for optimizing experimental design in leukemia and multiple myeloma research. The discussion builds on recent landmark findings and positions APExBIO’s Fludarabine as a pivotal tool for modern immuno-oncology workflows, differentiating itself from conventional product-focused content by bridging detailed mechanistic rationale with forward-looking translational strategy.
-
WM-8014: Precision KAT6A Inhibitor for Advanced Cancer Resea
2026-05-14
WM-8014 empowers cancer biology and epigenetic research with unmatched selectivity for KAT6A/B inhibition and minimal cytotoxicity. Its application in oncogene-induced senescence workflows demonstrates reproducible cell cycle arrest, enabling robust mechanistic studies and drug screening. Discover how WM-8014, supplied by APExBIO, optimizes experimental design and data reliability.
-
BRD4770: G9a Histone Methyltransferase Inhibitor in Cancer R
2026-05-13
BRD4770 empowers precise epigenetic modulation by selectively inhibiting G9a, directly impacting histone H3K9 methylation and cellular senescence pathways. Its robust performance in proliferation inhibition, especially in challenging models like PANC-1, sets a new experimental standard for cancer biology and chromatin research.
-
Ceruletide (Caerulein): Advanced Protocols for Pancreatic Re
2026-05-13
Ceruletide (Caerulein) is a gold-standard CCK analog for modeling pancreatic fibrosis and gastrointestinal function. This article delivers evidence-based protocols, advanced troubleshooting, and practical insights, translating the latest mechanistic discoveries into optimized experimental workflows for digestive disorder research.
-
Viperin Inhibits Coronaviruses via nsp8 Disruption and ddhCT
2026-05-12
Zhou et al. (2026) identified a dual antiviral mechanism for viperin against coronaviruses: enzymatic generation of ddhCTP, which impairs viral RNA synthesis in select strains, and direct disruption of the replication-transcription complex via interaction with non-structural protein 8 (nsp8). These insights expand the repertoire of host-driven antiviral strategies and highlight new targets for the development of broad-spectrum RNA virus replication inhibitors.
-
Lysosomal Exocytosis and Growth Factor Disruption in MPS IVA
2026-05-12
This study establishes enhanced lysosomal exocytosis and altered growth factor signaling as central drivers of cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA (MPS IVA). The findings move beyond the substrate accumulation paradigm, offering new mechanistic insights for skeletal disease research and lysosome-targeted intervention strategies.
-
Tolazoline in β Cell Electrophysiology: Beyond α2-Adrenergic
2026-05-11
Explore Tolazoline as an α2-adrenergic receptor antagonist, with unique focus on its nuanced role in β cell electrophysiology and insulin release. This article offers advanced experimental insight and protocol guidance distinct from conventional overviews.
-
GRE Combination Inhibits Melanogenesis via CREB/MITF Pathway
2026-05-11
This study demonstrates that a combination of glabridin, resveratrol, and ellagic acid (GRE) powerfully suppresses melanin synthesis, tyrosinase activity, and inflammation in cell models by downregulating the CREB/MITF axis. The findings provide a mechanistic rationale for GRE's use in pigmentation regulation research and potential therapeutic applications for hyperpigmentation disorders.